Retains Partner International to Further Develop Distribution Network for MiraCare(TM) Rapid HIV Test HALIFAX, Nov. 23 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in flow-through rapid diagnostic tests, announced today that it has engaged Swiss-based Partner International to assist in strengthening its European Union (EU) distribution network in anticipation of CE Mark approval. With the CE approval process advancing according to schedule, MedMira is increasing its efforts in building a solid distribution network to realize sales immediately following CE approval for its MiraCare(TM) Rapid HIV Test (MiraCare(TM) HIV). "We were looking for a partner that could act as an extension of our Sales & Marketing team to help us realize immediate product sales in the EU. Partner International's in-depth industry experience coupled with their strong European and global business connections make them an ideal partner in this market," said Giles Crouch, vice president of sales and marketing for MedMira. Crouch continued, "The flexibility of MiraCare(TM) HIV, for use with both whole blood and serum/plasma specimens, enables us to target all types of testing settings including hospitals, laboratories, pharmacies, voluntary clinics, and possibly the future over-the-counter (OTC) market in Europe. MiraCare(TM)'s adaptability will be a key differentiator for us in the critical EU market, which until now, has had limited choice in rapid HIV tests." MedMira will soon stand alone as the only rapid diagnostics manufacturer in the world to obtain all key international regulatory approvals for its rapid HIV tests; from the United States Food and Drug Administration (FDA), Health Canada, China State Food and Drug Administration (SFDA) and soon, the European Union CE Mark. These approvals coupled with exceptional performance in independent clinical studies, make MedMira a clear global leader for quality rapid HIV tests. "Our extensive market knowledge leads us to believe that MedMira's rapid HIV test will be the strongest product offering in Europe," said Joanne Ball, CEO of Partner International. "Our team is excited to collaborate with such a dynamic company who is leading the global market with the fastest rapid HIV test, and impressed by their outstanding quality and accurate results." According to EuroHIV, the European HIV/AIDS surveillance network, in a report released in November of 2004, newly diagnosed HIV infections increased by 26% in 2002 and 9% in 2003, and the number of women infected increased by 37% in 2003 compared to 33% in 2002. The fastest growing mode of HIV transmission was through heterosexual contact and is having an impact across all parts of Europe, with the highest rates being seen in Eastern Europe. It is estimated that over 2 million people in Europe are living with HIV. About Partner International Partner International GmbH is a business development company providing services to life sciences clients worldwide. With offices in Europe, North America, and associates located globally, Partner International is uniquely positioned to expedite the development of international strategic alliances. For more information visit http://www.partner-intl.com/. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow- through rapid diagnostic tests. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV and hepatitis C. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(R) rapid HIV tests, respectively. MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used in clinical laboratories, hospitals, and clinics where professional counselling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test, MedMira's over-the-counter (OTC) product, is available in pharmacies throughout Hong Kong and Macao Special Administrative Regions, in the People's Republic of China. MedMira delivers rapid diagnostic solutions to healthcare communities around the globe. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Guilin, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira's website at http://www.medmira.com/. DATASOURCE: MedMira Inc. CONTACT: Dr. James Smith, Investor Relations, Tel: (902) 450-1588, E-mail: ; Andrea Young, Corporate Communications, Tel. (902) 450-1588, Email:

Copyright